IBDEI065 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2665,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,2666,0)
 ;;=180.9^^27^240^8
 ;;^UTILITY(U,$J,358.3,2666,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2666,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,2666,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,2666,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,2667,0)
 ;;=203.02^^27^240^78
 ;;^UTILITY(U,$J,358.3,2667,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2667,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,2667,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,2667,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,2668,0)
 ;;=V10.91^^27^240^44
 ;;^UTILITY(U,$J,358.3,2668,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2668,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,2668,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,2668,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,2669,0)
 ;;=196.9^^27^240^62
 ;;^UTILITY(U,$J,358.3,2669,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2669,1,4,0)
 ;;=4^196.9
 ;;^UTILITY(U,$J,358.3,2669,1,5,0)
 ;;=5^Lymph Nodes
 ;;^UTILITY(U,$J,358.3,2669,2)
 ;;=^267313
 ;;^UTILITY(U,$J,358.3,2670,0)
 ;;=204.90^^27^240^63
 ;;^UTILITY(U,$J,358.3,2670,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2670,1,4,0)
 ;;=4^204.90
 ;;^UTILITY(U,$J,358.3,2670,1,5,0)
 ;;=5^Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,2670,2)
 ;;=^336854
 ;;^UTILITY(U,$J,358.3,2671,0)
 ;;=V10.82^^27^240^42
 ;;^UTILITY(U,$J,358.3,2671,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2671,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,2671,1,5,0)
 ;;=5^H/O Malig Melanoma
 ;;^UTILITY(U,$J,358.3,2671,2)
 ;;=^295240
 ;;^UTILITY(U,$J,358.3,2672,0)
 ;;=198.4^^27^240^76
 ;;^UTILITY(U,$J,358.3,2672,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2672,1,4,0)
 ;;=4^198.4
 ;;^UTILITY(U,$J,358.3,2672,1,5,0)
 ;;=5^Mets to Nervous System
 ;;^UTILITY(U,$J,358.3,2672,2)
 ;;=^267335
 ;;^UTILITY(U,$J,358.3,2673,0)
 ;;=202.80^^27^240^80
 ;;^UTILITY(U,$J,358.3,2673,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2673,1,4,0)
 ;;=4^202.80
 ;;^UTILITY(U,$J,358.3,2673,1,5,0)
 ;;=5^Non-Hodgkin's Lymphoma
 ;;^UTILITY(U,$J,358.3,2673,2)
 ;;=^87701
 ;;^UTILITY(U,$J,358.3,2674,0)
 ;;=V10.02^^27^240^53
 ;;^UTILITY(U,$J,358.3,2674,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2674,1,4,0)
 ;;=4^V10.02
 ;;^UTILITY(U,$J,358.3,2674,1,5,0)
 ;;=5^H/O of Malig Oral/Pharynx
 ;;^UTILITY(U,$J,358.3,2674,2)
 ;;=^295204
 ;;^UTILITY(U,$J,358.3,2675,0)
 ;;=V10.43^^27^240^54
 ;;^UTILITY(U,$J,358.3,2675,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2675,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,2675,1,5,0)
 ;;=5^H/O of Malig Ovary
 ;;^UTILITY(U,$J,358.3,2675,2)
 ;;=^295221
 ;;^UTILITY(U,$J,358.3,2676,0)
 ;;=V10.46^^27^240^55
 ;;^UTILITY(U,$J,358.3,2676,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2676,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,2676,1,5,0)
 ;;=5^H/O of Malig Prostate
 ;;^UTILITY(U,$J,358.3,2676,2)
 ;;=^295224
 ;;^UTILITY(U,$J,358.3,2677,0)
 ;;=V10.06^^27^240^56
 ;;^UTILITY(U,$J,358.3,2677,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2677,1,4,0)
 ;;=4^V10.06
 ;;^UTILITY(U,$J,358.3,2677,1,5,0)
 ;;=5^H/O of Malig Rectum/Rectosigmoid/Anus
 ;;^UTILITY(U,$J,358.3,2677,2)
 ;;=^295208
 ;;^UTILITY(U,$J,358.3,2678,0)
 ;;=200.00^^27^240^81
 ;;^UTILITY(U,$J,358.3,2678,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2678,1,4,0)
 ;;=4^200.00
 ;;^UTILITY(U,$J,358.3,2678,1,5,0)
 ;;=5^Reticulosarcoma
 ;;^UTILITY(U,$J,358.3,2678,2)
 ;;=^72635
 ;;^UTILITY(U,$J,358.3,2679,0)
 ;;=V10.83^^27^240^57
 ;;^UTILITY(U,$J,358.3,2679,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2679,1,4,0)
 ;;=4^V10.83
 ;;^UTILITY(U,$J,358.3,2679,1,5,0)
 ;;=5^H/O of Malig Skin
